New survey 'reinforces potential' for Futura Medical's erectile dysfunction gel
James Barder, chief executive of Futura Medical PLC (LON:FUM) runs Proactive through some new market research on their MED2002 product.
It found the majority of physicians in the US reckon their erectile dysfunction gel is an improvement over current ED therapies.
The research, carried out by Cello Health Consulting, also revealed that at least 10% of ED patients were contra-indicated – i.e. can’t be treated with – PDE5 inhibitors such as Viagra because of their existing medication. That’s higher than the 7.5% Futura believed it to be based on past research.